News | March 22, 2022
Hester Biosciences foray into pet care industry
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
Divsa's coverage across Central America bridges Barentz' leading positions in North and South America
The facility will produce 150 million vaccine doses per year
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Since 1993, Beghou Consulting has helped life sciences companies - especially emerging pharmaceutical companies - establish and manage commercial operations to better market and sell therapies
The investment will accelerate the overall Sarclisa development program
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Subscribe To Our Newsletter & Stay Updated
